Latest Peginterferon alfa-2b Stories
New research report “KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen” elaborated by FirstWord has been recently published by Market Publishers Ltd.
HUDDINGE, Sweden, February 18, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started. Phase 3 Program in brief: - TMC435-C208 or QUEST-1 includes approximately 375...
CORK, Ireland, Feb.
Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients.
WALTHAM, Mass., June 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical profiles provided to them, surveyed clinicians estimate that one year after the launch of Vertex Pharmaceuticals/Johnson & Johnson/Mitsubishi Tanabe Pharma's telaprevir and Merck's boceprevir, at least 90 percent of hepatitis C virus (HCV) patients will be treated with triple therapy regimens.
24 weeks of treatment could be sufficient to cure between 93 and 100% of treatment-naÃ¯ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to Telaprevir (TVR) with Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.
- Withering but not falling off, as a blossom that persists on a twig after flowering.